These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34963694)

  • 1. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
    Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
    Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
    Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
    Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
    Xia D; Kuo F; Hughes M; Lindeman N; Manning D; Files J; Strauss S; Kirkner G; Mohammed-Abreu A; Winer E; Tolaney SM; Lin NU; Dillon DA
    Am J Clin Pathol; 2024 May; 161(5):436-442. PubMed ID: 38104247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
    Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ
    Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
    Ichikawa H; Usui K; Aizawa M; Shimada Y; Muneoka Y; Kano Y; Sugai M; Moro K; Hirose Y; Miura K; Sakata J; Yabusaki H; Nakagawa S; Kawasaki T; Umezu H; Okuda S; Wakai T
    BMC Cancer; 2024 Jun; 24(1):719. PubMed ID: 38862927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
    Cenaj O; Ligon AH; Hornick JL; Sholl LM
    Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
    Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
    Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
    Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of apocrine salivary duct carcinoma.
    Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
    Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
    Nakamura K; Aimono E; Oba J; Hayashi H; Tanishima S; Hayashida T; Chiyoda T; Kosaka T; Hishida T; Kawakubo H; Kitago M; Okabayashi K; Funakoshi T; Okita H; Ikeda S; Takaishi H; Nishihara H
    Med Oncol; 2021 Mar; 38(4):36. PubMed ID: 33710417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.
    McAfee JL; Hoda RS; Hoyle C; McCoy L; Sprague C; Reddy CA; Koyfman SA; Geiger JL; Komforti MK; Griffith CC
    Mod Pathol; 2023 Oct; 36(10):100273. PubMed ID: 37423585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
    Ni R; Mulligan AM; Have C; O'Malley FP
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.
    Sapino A; Maletta F; Verdun di Cantogno L; Macrì L; Botta C; Gugliotta P; Scalzo MS; Annaratone L; Balmativola D; Pietribiasi F; Bernardi P; Arisio R; Viberti L; Guzzetti S; Orlassino R; Ercolani C; Mottolese M; Viale G; Marchiò C
    Oncologist; 2014 Nov; 19(11):1118-26. PubMed ID: 25323485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
    Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
    Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
    Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
    J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups.
    Yang SR; Bouhlal Y; De La Vega FM; Ballard M; Kuo CJ; Vilborg A; Jensen G; Allison K
    Mod Pathol; 2020 Aug; 33(8):1546-1556. PubMed ID: 32161378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
    Ryu HJ; Koh YW; Yoon SO
    Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.